2021
Prospective Cohort Study of Infective Endocarditis in People Who Inject Drugs
PERICAS, J. M., J. LLOPIS, E. ATHAN, M. HERNANDEZ-MENESES, M. M. HANNAN et. al.Základní údaje
Originální název
Prospective Cohort Study of Infective Endocarditis in People Who Inject Drugs
Autoři
PERICAS, J. M., J. LLOPIS, E. ATHAN, M. HERNANDEZ-MENESES, M. M. HANNAN, D. R. MURDOCH, Z. KANAFANI, Tomáš FREIBERGER (203 Česká republika, domácí), J. STRAHILEVITZ, N. FERNANDEZ-HIDALGO, C. LAMAS, E. DURANTE-MANGONI, P. TATTEVIN, F. NACINOVICH, V. H. CHU a J. M. MIRO (garant)
Vydání
Journal of the American College of Cardiology, New York, Elsevier Science INC, 2021, 0735-1097
Další údaje
Jazyk
angličtina
Typ výsledku
Článek v odborném periodiku
Obor
30201 Cardiac and Cardiovascular systems
Stát vydavatele
Spojené státy
Utajení
není předmětem státního či obchodního tajemství
Odkazy
Impakt faktor
Impact factor: 27.203
Kód RIV
RIV/00216224:14110/21:00121771
Organizační jednotka
Lékařská fakulta
UT WoS
000631946500004
Klíčová slova anglicky
cardiac surgery; HIV; infective endocarditis; opioid crisis; people who inject drugs; Staphylococcus aureus
Příznaky
Mezinárodní význam, Recenzováno
Změněno: 12. 12. 2022 09:24, Mgr. Tereza Miškechová
Anotace
V originále
BACKGROUND Infective endocarditis (IE) in people who inject drugs (PWID) is an emergent public health problem. OBJECTIVES The purpose of this study was to investigate IE in PWID and compare it with IE in non-PWID patients. METHODS Two prospective cohort studies (ICE-PCS and ICE-Plus databases, encompassing 8,112 IE episodes from 2000 to 2006 and 2008 to 2012, with 64 and 34 sites and 28 and 18 countries, respectively). Outcomes were compared between PWID and non-PWID patients with IE. Logistic regression analyses were performed to investigate risk factors for 6-month mortality and relapses amongst PWID. RESULTS A total of 7,616 patients (591 PWID and 7,025 non-PWID) were included. PWID patients were significantly younger (median 37.0 years [interquartile range: 29.5 to 44.2 years] vs. 63.3 years [interquartile range: 49.3 to 74.0 years]; p < 0.001), male (72.5% vs. 67.4%; p = 0.007), and presented lower rates of comorbidities except for human immunodeficiency virus, liver disease, and higher rates of prior IE. Amongst IE cases in PWID, 313 (53%) episodes involved left-side valves and 204 (34.5%) were purely left-sided IE. PWID presented a larger proportion of native IE (90.2% vs. 64.4%; p < 0.001), whereas prosthetic-IE and cardiovascular implantable electronic device-IE were more frequent in non-PWID (9.3% vs. 27.0% and 0.5% vs. 8.6%; both p < 0.001). Staphylococcus aureus caused 65.9% and 26.8% of cases in PWID and non-PWID, respectively (p < 0.001). PWID presented higher rates of systemic emboli (51.1% vs. 22.5%; p < 0.001) and persistent bacteremia (14.7% vs. 9.3%; p < 0.001). Cardiac surgery was less frequently performed (39.5% vs. 47.8%; p < 0.001), and in-hospital and 6-month mortality were lower in PWID (10.8% vs. 18.2% and 14.4% vs. 22.2%; both p < 0.001), whereas relapses were more frequent in PWID (9.5% vs. 2.8%; p < 0.001). Prior IE, left-sided IE, polymicrobial etiology, intracardiac complications, and stroke were risk factors for 6-month mortality, whereas cardiac surgery was associated with lower mortality in the PWID population. CONCLUSIONS A notable proportion of cases in PWID involve left-sided valves, prosthetic valves, or are caused by microorganisms other than S. aureus. (C) 2021 by the American College of Cardiology Foundation.